Unicycive Therapeutics (NASDAQ: UNCY)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.160 | -0.240 | -0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Unicycive Therapeutics (NASDAQ: UNCY) through any online brokerage.
Other companies in Unicycive Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Brickell Biotech (NASDAQ:BBI), Cyclacel Pharmaceuticals (NASDAQ:CYCC) and BioRestorative Therapies (NASDAQ:BRTX).
The latest price target for Unicycive Therapeutics (NASDAQ: UNCY) was reported by HC Wainwright & Co. on Wednesday, June 8, 2022. The analyst firm set a price target for 9.00 expecting UNCY to rise to within 12 months (a possible 997.56% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Unicycive Therapeutics (NASDAQ: UNCY) is $0.82 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Unicycive Therapeutics.
Unicycive Therapeutics’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Unicycive Therapeutics.
Unicycive Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.